300391 长药控股
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-172.953-121.642-2.8616.1273.300
总资产报酬率 ROA (%)-5.537-17.244-0.5971.1040.816
投入资产回报率 ROIC (%)-18.861-42.419-1.2502.4580.874

边际利润分析
销售毛利率 (%)4.92716.36721.46822.68621.697
营业利润率 (%)-273.879-55.9234.9497.4904.839
息税前利润/营业总收入 (%)-214.876-51.7757.5888.3836.246
净利润/营业总收入 (%)-277.320-59.0652.7596.7465.458

收益指标分析
经营活动净收益/利润总额(%)46.142-2.344176.705153.93580.122
价值变动净收益/利润总额(%)0.000-9.93176.834-0.666-4.204
营业外收支净额/利润总额(%)1.2391.659-11.305-11.744-0.612

偿债能力分析
流动比率 (X)0.9961.1321.1270.9760.807
速动比率 (X)0.9711.1041.0890.8830.711
资产负债率 (%)76.15170.47653.48461.81569.048
带息债务/全部投入资本 (%)93.38779.14953.13347.998--
股东权益/带息债务 (%)1.79622.92384.65488.54777.101
股东权益/负债合计 (%)0.6018.03541.83331.71724.020
利息保障倍数 (X)-3.441-10.1702.4164.9914.349

营运能力分析
应收账款周转天数 (天)4,224.995461.156312.784195.7640.000
存货周转天数 (天)136.75820.00936.15844.0560.000